Adenovirus Disease Following Pediatric Liver Transplantation: 10-Year Experience From a Large Pediatric Transplant Program.

BACKGROUND

Human adenovirus in immunocompromised patients can be life-threatening. We describe the prevalence, clinical presentation, and treatment of adenovirus after pediatric liver transplantation at a large transplant center.

METHODS

We performed a retrospective cohort study of adenovirus infection in children from 2013 to 2022. We compared incidence, clinical characteristics, and outcomes of post-transplant children by adenovirus treatment status.

RESULTS

Adenovirus disease developed in 26% (84/320) children after liver transplant. Median age at liver transplant was 17.5 months, 48% were female; 50% had biliary atresia. Fever (53%), gastrointestinal symptoms (48%), and hepatitis (41%) were the most common clinical presentations at diagnosis. Median time to adenovirus diagnosis was 80 days (IQR 19-260) with 40% (n = 31/84) identified within 30 days post-transplant. Disseminated adenovirus (≥ 2 organ involvement) occurred in 24% (20/84). Fourteen patients (17%) received cidofovir, and most (13/14, 93%) had DNAemia, compared to 57% untreated patients with DNAemia (p = 0.013). Median peak adenovirus load was 491 805 copies/mL (IQR 24 800-1 900 000) in treated vs. 1000 copies/mL (IQR 595-794 794) in untreated patients (p < 0.001). Overall mortality was 8% (7/84).

CONCLUSION

The incidence of symptomatic and disseminated adenovirus disease was high in our pediatric liver transplant patients, particularly within 30 days post-transplant. Patients who received cidofovir treatment presented with high viral load and had the highest mortality. There is a critical need for evidence-based guidance for early antiviral management of adenovirus disease after pediatric liver transplant.